SGLT2 protein expression is increased in human diabetic nephropathy: SGLT2 protein inhibition decreases renal lipid accumulation, inflammation, and the development of nephropathy in diabetic mice

Journal of Biological Chemistry

Volumn 292, Issue 13, 2017, Pages 5335-5348

  Wang, Xiaoxin X ^a,b   Levi, Jonathan ^c   Luo, Yuhuan ^a   Myakala, Komuraiah ^a   Herman Edelstein, Michal ^d   Qiu, Liru ^a   Wang, Dong ^a   Peng, Yingqiong ^a   Grenz, Almut ^a   Lucia, Scott ^a   Dobrinskikh, Evgenia ^a   D'Agati, Vivette D ^e   Koepsell, Hermann ^f   Kopp, Jeffrey B ^c   Rosenberg, Avi Z ^g   Levi, Moshe ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b Veterans Affairs Eastern Colorado Healthcare System   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^d TEL AVIV UNIVERSITY   (Israel)

^e College of Physicians and Surg ^*  (United States)

^f UNIVERSITY OF WÜRZBURG   (Germany)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOSYNTHESIS; BLOOD PRESSURE; DISEASES; ENZYME ACTIVITY; FATTY ACIDS; MAMMALS; PATHOLOGY;

DIABETIC NEPHROPATHY; ELEMENT-BINDING PROTEINS; EXTRACELLULAR MATRIX PROTEIN; GLUCOSE TRANSPORTERS; IMMUNOFLUORESCENCE MICROSCOPY; SYSTOLIC BLOOD PRESSURE; THIOBARBITURIC ACID REACTING SUBSTANCES; TRANSCRIPTIONAL FACTORS;

ENZYME INHIBITION;

ACYL COENZYME A DESATURASE; ALBUMIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSINOGEN; ANTIDIABETIC AGENT; BINDING PROTEIN; CARBOHYDRATE RESPONSIVE ELEMENT BINDING PROTEIN BETA; CD68 ANTIGEN; CHOLESTEROL ESTER; DIACYLGLYCEROL ACYLTRANSFERASE 1; DIPEPTIDYL CARBOXYPEPTIDASE; FIBRONECTIN; HEMOGLOBIN A1C; INSULIN; JNJ 39933673; MESSENGER RNA; NEPHRIN; OSTEOPONTIN; PYRUVATE KINASE; PYRUVATE KINASE L; RENIN; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2; STEAROYL COA DESATURASE 1; SYNAPTOPODIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRANSCRIPTION FACTOR RELA; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; BRUSH BORDER; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG POTENCY; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; FEMALE; GLOMERULUS; GLUCONEOGENESIS; GLUCOSE ABSORPTION; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; IC50; INSULIN BLOOD LEVEL; KIDNEY BIOPSY; KIDNEY HYPERTROPHY; KIDNEY MASS; KIDNEY PROXIMAL TUBULE; LIPID METABOLISM; LIPID STORAGE; MACROPHAGE; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PODOCYTE; PROPHYLAXIS; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; URINARY EXCRETION; ANIMAL; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; GENETICS; INFLAMMATION; KIDNEY DISEASE; METABOLISM;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; HUMANS; INFLAMMATION; KIDNEY DISEASES; LIPID METABOLISM; MICE; RNA, MESSENGER; SODIUM-GLUCOSE TRANSPORTER 2; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85016626296     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M117.779520     Document Type: Article

References (74)

1. Boyle, J. P., Thompson, T. J., Gregg, E. W., Barker, L. E., and Williamson, D. F. (2010) Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul. Health Metr. 8, 29
2. Odermatt, A. (2011) The Western-style diet: a major risk factor for impaired kidney function and chronic kidney disease. Am. J. Physiol. Renal Physiol. 301, F919-F931
3. Thomas, G., Sehgal, A. R., Kashyap, S. R., Srinivas, T. R., Kirwan, J. P., and Navaneethan, S. D. (2011) Metabolic syndrome and kidney disease: a systematic review and meta-analysis. Clin. J. Am. Soc. Nephrol. 6, 2364-2373
4. Bobulescu, I. A. (2010) Renal lipid metabolism and lipotoxicity. Curr. Opin. Nephrol. Hypertens. 19, 393-402
5. Forbes, J. M., Coughlan, M. T., and Cooper, M. E. (2008) Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 57, 1446-1454
6. Gurley, S. B., and Coffman, T. M. (2007) The renin-angiotensin system and diabetic nephropathy. Semin. Nephrol. 27, 144-152
7. Hunley, T. E., Ma, L. J., and Kon, V. (2010) Scope and mechanisms of obesity-related renal disease. Curr. Opin. Nephrol. Hypertens. 19, 227-234
8. Mauer, S. M. (1994) Structural-functional correlations of diabetic nephropathy. Kidney Int. 45, 612-622
9. Qian, Y., Feldman, E., Pennathur, S., Kretzler, M., and Brosius, F. C., 3rd (2008) From fibrosis to sclerosis: mechanisms of glomerulosclerosis in diabetic nephropathy. Diabetes 57, 1439-1445
10. Ruan, X. Z., Varghese, Z., and Moorhead, J. F. (2009) An update on the lipid nephrotoxicity hypothesis. Nat. Rev. Nephrol. 5, 713-721
11. Weinberg, J. M. (2006) Lipotoxicity. Kidney Int. 70, 1560-1566
12. Zhu, Y., Usui, H. K., and Sharma, K. (2007) Regulation of transforming growth factor β in diabetic nephropathy: implications for treatment. Semin. Nephrol. 27, 153-160
13. de Boer, I. H., Rue, T. C., Hall, Y. N., Heagerty, P. J., Weiss, N. S., and Himmelfarb, J. (2011) Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 305, 2532-2539
14. Rosolowsky, E. T., Skupien, J., Smiles, A. M., Niewczas, M., Roshan, B., Stanton, R., Eckfeldt, J. H., Warram, J. H., and Krolewski, A. S. (2011) Risk for ESRD in type 1 diabetes remains high despite renoprotection. J. Am. Soc. Nephrol. 22, 545-553
15. Farber, S. J., Berger, E. Y., and Earle, D. P. (1951) Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose. J. Clin. Invest. 30, 125-129
16. Vallon, V., Rose, M., Gerasimova, M., Satriano, J., Platt, K. A., Koepsell, H., Cunard, R., Sharma, K., Thomson, S. C., and Rieg, T. (2013) Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am. J. Physiol. Renal Physiol. 304, F156-F167
17. Vallon, V., Gerasimova, M., Rose, M. A., Masuda, T., Satriano, J., Mayoux, E., Koepsell, H., Thomson, S. C., and Rieg, T. (2014) SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am. J. Physiol. Renal Physiol. 306, F194-F204
18. Rahmoune, H., Thompson, P. W., Ward, J. M., Smith, C. D., Hong, G., and Brown, J. (2005) Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 54, 3427-3434
19. Vallon, V. (2011) The proximal tubule in the pathophysiology of the diabetic kidney. Am. J. Physiol. Regul. Integr. Comp. Physiol. 300, R1009-R1022
20. Vallon, V., Platt, K. A., Cunard, R., Schroth, J., Whaley, J., Thomson, S. C., Koepsell, H., and Rieg, T. (2011) SGLT2 mediates glucose reabsorption in the early proximal tubule. J. Am. Soc. Nephrol. 22, 104-112
21. Mather, A., and Pollock, C. (2011) Glucose handling by the kidney. Kidney Int. Suppl. 120, S1-S6
22. Gorboulev, V., Schurmann, A., Vallon, V., Kipp, H., Jaschke, A., Klessen, D., Friedrich, A., Scherneck, S., Rieg, T., Cunard, R., Veyhl-Wichmann, M., Srinivasan, A., Balen, D., Breljak, D., Rexhepaj, R., et al. (2012) Naβ-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes 61, 187-196
23. S?krtic?, M., and Cherney, D. Z. (2015) Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy. Curr. Opin. Nephrol. Hypertens. 24, 96-103
24. Stanton, R. C. (2014) Sodium glucose transport 2 (SGLT2) inhibition decreases glomerular hyperfiltration: is there a role for SGLT2 inhibitors in diabetic kidney disease? Circulation 129, 542-544
25. Thomson, S. C., Rieg, T., Miracle, C., Mansoury, H., Whaley, J., Vallon, V., and Singh, P. (2012) Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am. J. Physiol. Regul. Integr. Comp. Physiol. 302, R75-R83
26. Vallon, V. (2015) The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu. Rev. Med. 66, 255-270
27. De Nicola, L., Gabbai, F. B., Liberti, M. E., Sagliocca, A., Conte, G., and Minutolo, R. (2014) Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes. Am. J. Kidney Dis. 64, 16-24
28. Gallo, L. A., Wright, E. M., and Vallon, V. (2015) Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. Diab. Vasc. Dis. Res. 12, 78-89
29. Gembardt, F., Bartaun, C., Jarzebska, N., Mayoux, E., Todorov, V. T., Hohenstein, B., and Hugo, C. (2014) The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension. Am. J. Physiol. Renal Physiol. 307, F317-F325
30. Kojima, N., Williams, J. M., Takahashi, T., Miyata, N., and Roman, R. J. (2013) Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats. J. Pharmacol. Exp. Ther. 345, 464-472
31. Komala, M. G., Panchapakesan, U., Pollock, C., and Mather, A. (2013) Sodium glucose cotransporter 2 and the diabetic kidney. Curr. Opin. Nephrol. Hypertens. 22, 113-119
32. Novikov, A., and Vallon, V. (2015) Sodium glucose cotransporter 2 inhibition in the diabetic kidney: an update. Curr. Opin. Nephrol. Hypertens. 25, 50-58
33. Ishibashi, Y., Matsui, T., and Yamagishi, S. (2016) Tofogliflozin, a highly selective inhibitor of SGLT2 blocks proinflammatory and proapoptotic effects of glucose overload on proximal tubular cells partly by suppressing oxidative stress generation. Horm. Metab. Res. 48, 191-195
34. Gallo, L. A., Ward, M. S., Fotheringham, A. K., Zhuang, A., Borg, D. J., Flemming, N. B., Harvie, B. M., Kinneally, T. L., Yeh, S. M., McCarthy, D. A., Koepsell, H., Vallon, V., Pollock, C., Panchapakesan, U., and Forbes, J. M. (2016) Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice. Sci. Rep. 6, 26428
35. Mende, C. W. (2017) Diabetes and kidney disease: the role of sodiumglucose cotransporter-2 (SGLT2) and SGLT2 inhibitors in modifying disease outcomes. Curr. Med. Res. Opin. 33, 541-551
36. Tsimihodimos, V., Filippatos, T. D., Fillippas-Ntekouan, S., and Elisaf, M. S. (2016) Renoprotective effects of SGLT2 inhibitors: Beyond glucose reabsorption inhibition. Curr. Vasc. Pharmacol. 10.2174/1570161114666161007163426
37. Vallon, V., and Thomson, S. C. (2017) Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia 60, 215-225
38. Vallianou, N. G., Geladari, E., and Kazazis, C. E. (2016) SGLT2 inhibitors: their pleiotropic properties. Diabetes Metab. Syndr. 10.1016/j.dsx.2016.12.003
39. Mudaliar, S., Polidori, D., Zambrowicz, B., and Henry, R. R. (2015) Sodium-glucose cotransporter inhibitors: effects on renal and intestinal glucose transport: from bench to bedside. Diabetes Care 38, 2344-2353
40. Bank, N., and Aynedjian, H. S. (1990) Progressive increases in luminal glucose stimulate proximal sodium absorption in normal and diabetic rats. J. Clin. Invest. 86, 309-316
41. Persson, P., Hansell, P., and Palm, F. (2010) Tubular reabsorption and diabetes-induced glomerular hyperfiltration. Acta Physiol. 200, 3-10
42. Schnermann, J. (2015) Concurrent activation of multiple vasoactive signaling pathways in vasoconstriction caused by tubuloglomerular feedback: a quantitative assessment. Annu. Rev. Physiol. 77, 301-322
43. Thomas, M. C. (2014) Renal effects of dapagliflozin in patients with type 2 diabetes. Ther. Adv. Endocrinol. Metab. 5, 53-61
44. Vallon, V., and Thomson, S. C. (2012) Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney. Annu. Rev. Physiol. 74, 351-375
45. Jiang, T., Wang, X. X., Scherzer, P., Wilson, P., Tallman, J., Takahashi, H., Li, J., Iwahashi, M., Sutherland, E., Arend, L., and Levi, M. (2007) Farnesoid X receptor modulates renal lipid metabolism, fibrosis, and diabetic nephropathy. Diabetes 56, 2485-2493
46. Sun, L., Halaihel, N., Zhang, W., Rogers, T., and Levi, M. (2002) Role of sterol regulatory element-binding protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus. J. Biol. Chem. 277, 18919-18927
47. Proctor, G., Jiang, T., Iwahashi, M., Wang, Z., Li, J., and Levi, M. (2006) Regulation of renal fatty acid and cholesterol metabolism, inflammation, and fibrosis in Akita and OVE26 mice with type 1 diabetes. Diabetes 55, 2502-2509
48. Wang, Z., Jiang, T., Li, J., Proctor, G., McManaman, J. L., Lucia, S., Chua, S., and Levi, M. (2005) Regulation of renal lipid metabolism, lipid accumulation, and glomerulosclerosis in FVBdb/db mice with type 2 diabetes. Diabetes 54, 2328-2335
49. Guebre-Egziabher, F., Alix, P. M., Koppe, L., Pelletier, C. C., Kalbacher, E., Fouque, D., and Soulage, C. O. (2013) Ectopic lipid accumulation: a potential cause for metabolic disturbances and a contributor to the alteration of kidney function. Biochimie 95, 1971-1979
50. Wang, X. X., Edelstein, M. H., Gafter, U., Qiu, L., Luo, Y., Dobrinskikh, E., Lucia, S., Adorini, L., D'Agati, V. D., Levi, J., Rosenberg, A., Kopp, J. B., Gius, D. R., Saleem, M. A., and Levi, M. (2015)Gprotein-coupled bile acid receptor TGR5 activation inhibits kidney disease in obesity and diabetes. J. Am. Soc. Nephrol. 27, 1362-1378
51. Herman-Edelstein, M., Scherzer, P., Tobar, A., Levi, M., and Gafter, U. (2014) Altered renal lipid metabolism and renal lipid accumulation in human diabetic nephropathy. J. Lipid Res. 55, 561-572
52. Chang-Chen, K. J., Mullur, R., and Bernal-Mizrachi, E. (2008) Beta-cell failure as a complication of diabetes. Rev. Endocr. Metab. Disord. 9, 329-343
53. Tak, E., Ridyard, D., Kim, J. H., Zimmerman, M., Werner, T., Wang, X. X., Shabeka, U., Seo, S. W., Christians, U., Klawitter, J., Moldovan, R., Garcia, G., Levi, M., Haase, V., Ravid, K., Eltzschig, H. K., and Grenz, A. (2014) CD73-dependent generation of adenosine and endothelial Adora2b signaling attenuate diabetic nephropathy. J. Am. Soc. Nephrol. 25, 547-563
54. Barnett, A. H., Mithal, A., Manassie, J., Jones, R., Rattunde, H., Woerle, H. J., Broedl, U. C., and EMPA-REG RENAL trial investigators. (2014) Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2, 369-384
55. Ferrannini, E., Veltkamp, S. A., Smulders, R. A., and Kadokura, T. (2013) Renal glucose handling: impact of chronic kidney disease and sodiumglucose cotransporter 2 inhibition in patients with type 2 diabetes. Diabetes Care 36, 1260-1265
56. Vrhovac, I., Balen Eror, D., Klessen, D., Burger, C., Breljak, D., Kraus, O., Radović, N., Jadrijević, S., Aleksic, I., Walles, T., Sauvant, C., Sabolić, I., and Koepsell, H. (2015) Localizations of Naβ-D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart. Pflugers Arch. 467, 1881-1898
57. Panchapakesan, U., Pegg, K., Gross, S., Komala, M. G., Mudaliar, H., Forbes, J., Pollock, C., and Mather, A. (2013) Effects of SGLT2 inhibition in human kidney proximal tubular cells-renoprotection in diabetic nephropathy? PLoS One 8, e54442
58. Gerich, J. E. (2010) Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabetic Med. 27, 136-142
59. Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., Broedl, U. C., and Woerle, H. J. (2014) Metabolic response to sodiumglucose cotransporter 2 inhibition in type 2 diabetic patients. J. Clin. Invest. 124, 499-508
60. Maeda, S., Matsui, T., Takeuchi, M., and Yamagishi, S. (2013) Sodiumglucose cotransporter 2-mediated oxidative stress augments advanced glycation end products-induced tubular cell apoptosis. Diabetes Metab. Res. Rev 29, 406-412
61. Antonioli, L., Blandizzi, C., Csoka, B., Pacher, P., and Hasko, G. (2015) Adenosine signalling in diabetes mellitus-pathophysiology and therapeutic considerations. Nat. Rev. Endocrinol. 11, 228-241
62. Pawelczyk, T., Grden, M., Rzepko, R., Sakowicz, M., and Szutowicz, A. (2005) Region-specific alterations of adenosine receptors expression level in kidney of diabetic rat. Am. J. Pathol. 167, 315-325
63. Faulhaber-Walter, R., Chen, L., Oppermann, M., Kim, S. M., Huang, Y., Hiramatsu, N., Mizel, D., Kajiyama, H., Zerfas, P., Briggs, J. P., Kopp, J. B., and Schnermann, J. (2008) Lack of A1 adenosine receptors augments diabetic hyperfiltration and glomerular injury. J. Am. Soc. Nephrol. 19, 722-730
64. Awad, A. S., Huang, L., Ye, H., Duong, E. T., Bolton, W. K., Linden, J., and Okusa, M. D. (2006) Adenosine A2A receptor activation attenuates inflammation and injury in diabetic nephropathy. Am. J. Physiol. Renal Physiol. 290, F828-F837
65. Roa, H., Gajardo, C., Troncoso, E., Fuentealba, V., Escudero, C., Yanez, A., Sobrevia, L., Pastor-Anglada, M., Quezada, C., and San Martin, R. (2009) Adenosine mediates transforming growth factor-β1 release in kidney glomeruli of diabetic rats. FEBS Lett. 583, 3192-3198
66. Cardenas, A., Toledo, C., Oyarzun, C., Sepulveda, A., Quezada, C., Guillen-Gomez, E., Diaz-Encarnacion, M. M., Pastor-Anglada, M., and San Martin, R. (2013) Adenosine A(2B) receptor-mediated VEGF induction promotes diabetic glomerulopathy. Lab. Invest. 93, 135-144
67. Terami, N., Ogawa, D., Tachibana, H., Hatanaka, T., Wada, J., Nakatsuka, A., Eguchi, J., Horiguchi, C. S., Nishii, N., Yamada, H., Takei, K., and Makino, H. (2014) Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. PLoS One 9, e100777
68. Brosius, F. C., and Coward, R. J. (2014) Podocytes, signaling pathways, and vascular factors in diabetic kidney disease. Adv. Chronic Kidney Dis. 21, 304-310
69. Jiang, T., Wang, Z., Proctor, G., Moskowitz, S., Liebman, S. E., Rogers, T., Lucia, M. S., Li, J., and Levi, M. (2005) Diet-induced obesity in C57BL/6J mice causes increased renal lipid accumulation and glomerulosclerosis via a sterol regulatory element-binding protein-1c-dependent pathway. J. Biol. Chem. 280, 32317-32325
70. Giral, H., Cranston, D., Lanzano, L., Caldas, Y., Sutherland, E., Rachelson, J., Dobrinskikh, E., Weinman, E. J., Doctor, R. B., Gratton, E., and Levi, M. (2012) NHE3 regulatory factor 1 (NHERF1) modulates intestinal sodiumdependent phosphate transporter (NaPi-2b) expression in apical microvilli. J. Biol. Chem. 287, 35047-35056
71. Caldas, Y. A., Giral, H., Cortazar, M. A., Sutherland, E., Okamura, K., Blaine, J., Sorribas, V., Koepsell, H., and Levi, M. (2011) Liver X receptoractivating ligands modulate renal and intestinal sodium-phosphate transporters. Kidney Int. 80, 535-544
72. Wang, X. X., Jiang, T., Shen, Y., Adorini, L., Pruzanski, M., Gonzalez, F. J., Scherzer, P., Lewis, L., Miyazaki-Anzai, S., and Levi, M. (2009) The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria. Am. J. Physiol. Renal Physiol. 297, F1587-F1596
73. Wang, X. X., Jiang, T., Shen, Y., Caldas, Y., Miyazaki-Anzai, S., Santamaria, H., Urbanek, C., Solis, N., Scherzer, P., Lewis, L., Gonzalez, F. J., Adorini, L., Pruzanski, M., Kopp, J. B., Verlander, J. W., and Levi, M. (2010) Diabetic nephropathy is accelerated by farnesoid X receptor deficiency and inhibited by farnesoidXreceptor activation in a type 1 diabetes model. Diabetes 59, 2916-2927
74. Wang, X. X., Jiang, T., Shen, Y., Santamaria, H., Solis, N., Arbeeny, C., and Levi, M. (2011) Vitamin D receptor agonist doxercalciferol modulates dietary fat-induced renal disease and renal lipid metabolism. Am. J. Physiol. Renal Physiol. 300, F801-F810